Loading stock data…
KRYS
$275.65+9.61 (+3.61%)
Market OpenUpdated 12:40 PM EDT
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Krystal Biotech, Inc. in the Healthcare sector is trading at $275.65. The stock is currently near its 52-week high of $298.30, remaining 26.2% above its 200-day moving average. Technical signals show neutral RSI of 54 and bearish MACD signal, explaining why KRYS maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$275.65
Potential Downside
49.3%
Whystock Fair Value$139.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$315.00+14.3%
Range$241.00 – $380.00
Fundamentals
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremag...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.12B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
40.28
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.03%
Volume
Today's trading volume
318,873
Recent News
How The Krystal Biotech (KRYS) Narrative Is Shifting With Vyjuvek And Late Stage Pipeline
Analysts have been lifting fair value estimates for Krystal Biotech, with the updated Street number moving from US$291.22 to US$315.00, roughly a US$24 shift in the latest models. That change lines up with recent research that links price targets in the US$280 to US$370 range to views on Vyjuvek assumptions, FY25 forecasts, and how much credit to give the late stage pipeline. As you read on, you will see how to track these evolving calls so you can keep your own Krystal Biotech view...
Is Paymentus Stock a Buy After Palisades Investment Partners Increased Its Stake By $6 Million?
Paymentus delivers cloud-based bill payment technology to major enterprises across regulated and service-intensive industries.
Is Amprius Technologies Stock a Buy After Palisades Investment Partners Initiated a Position Worth $4.8 Million?
Amprius Technologies manufactures silicon nanowire lithium-ion batteries for aerospace, defense, and electric mobility markets.
Palisades Investment Partners Initiated a Position in SkyWater Technology Stock. What Does This Mean for Investors?
SkyWater Technology delivers custom semiconductor solutions for sectors including aerospace, automotive, and industrial IoT.
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of +20.40% and +211.90%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?